Vela Diagnostics Announces Launch Of CE-IVD Non-Small Cell Lung Cancer Next-Generation Sequencing Panel

Singapore (February 10, 2015) – Vela Diagnostics announced today the CE-IVD launch of the Sentosa® SQ Non-Small Cell Lung Cancer (NSCLC) Panel for Next-Generation Sequencing (NGS)-based gene sequence variant detection and identification. This is the third in a series of NGS oncology panels from Vela Diagnostics, which recently launched the CE-IVD Sentosa® SQ Melanoma Panel1 and the CE-IVD Sentosa® SQ Colorectal Cancer (CRC) Panel1.

Lung cancer is the most prevalent cancer and the leading cause of cancer deaths in males, making up 17% of total new cancer cases and 23% of total cancer deaths worldwide.2 Overall, the chance that a man will develop lung cancer in his lifetime is about 1 in 13; for a woman, the risk is about 1 in 16. These numbers include both smokers and non-smokers. 3

Cancer is associated with various different genetic alterations leading to aberrant cell proliferation. New therapies are based on an improved understanding of these genetic alterations.4 Therefore, molecular classification of the tumors is becoming increasingly important to determine the right therapy for each individual patient.

Vela Diagnostics’ Sentosa® SQ NSCLC Panel quickly and reliably identifies these cancercausing mutations by simultaneous detection of 113 hot spots in 11 genes. It exhibits a Limit of Detection (LOD) of 5% with minimal DNA requirement of 5 ng per sample and has a clinical sensitivity of 100% (95% CI: 95% – 100%).

The Sentosa® SQ NSCLC Panel is validated on the automated Sentosa® NGS workflow which enables automated sample extraction, library preparation and comprehensive automated results reporting. It also significantly reduces hands-on time and minimizes sample input requirements.

Vela Diagnostics offers automated platforms that support both NGS and PCR workflows. The workflows share the Sentosa® SX 101 automatic pipetting system thereby increasing efficiency and flexibility. Currently Vela Diagnostics offers 30 PCR tests (27 CE-IVD)1 and four NGS tests (three CE-IVD)1. Three additional NGS panels are planned for 2015.

About Vela Diagnostics

Vela Diagnostics is a worldwide provider of integrated molecular diagnostics workflows that address individual testing needs. Established in 2011 with its global headquarters in Singapore, Vela Diagnostics provides innovative test and data reporting solutions for Real-Time PCR and Next-Generation Sequencing. Integrating both PCR and NGS solutions to test for infectious diseases and oncologic targets increases flexibility and efficiency of the workflow and enables laboratories to overcome complex diagnostic challenges. Reliable and multi-purpose instruments help reduce the cost for optimal efficiency across laboratories of all sizes. With scalability and open-channel capabilities, laboratories also benefit from the flexibility and versatility of the systems available. For more information, please visit www.veladx.com.

Media Contact
Esther Chew
Marketing Communications Manager
esther.chew@veladx.com
+65 6690 6016

1 Availability status subject to country regulatory approvals. Refer to the website for more details.

2 Jemal, A. et al., (2011). Global cancer statistics. CA Cancer J Clin. 61(2), 69–90.

3 http://www.cancer.org/cancer/lungcancer-­-non-­-smallcell/detailedguide/non-­-small-­-cell-­-lung-­-cancer-­-key-­- statistics

4 http://www.cancer.org/cancer/lungcancer-­-non-­-smallcell/detailedguide/non-­-small-­-cell-­-lung-­-cancer-­- treating-­-targeted-­-therapies

Help employers find you! Check out all the jobs and post your resume.

Back to news